Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of AZD1775 and Olaparib in Patients With Refractory Solid Tumours

NCT02511795 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02511795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02511795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of AZD1775 and Olaparib in Patients With Refractory Solid Tumours
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
August 6, 2015
Completion date
October 16, 2019
Enrollment
128 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

refractory solid tumours, relapsed small cell lung cancer (sclc)